Full Text of PDF (332k)
Article in Japanese
Abstract
Case Report
A case involving careful control of cytomegalovirus infection during immunosuppressive therapy for severe immune-related adverse events caused by nivolumab
Yoshiaki Aminoa Shinya Uematsua Takahiro Yoshizawaa Ken Uchiboria Atsushi Horiikeb Makoto Nishioa
aDepartment of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research
bDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine
ABSTRACT
A 72-year-old male with metastatic non-small cell lung cancer received nivolumab as second line treatment. Two series of nivolumab were administered while prednisolone (PSL) was used for control of enteritis, an immune-related adverse event (irAE). After the third initiation of nivolumab simultaneously with 10 mg/day of PSL, severe cholangitis leading to emergency admission to hospital occurred. Because of his poor response to 2 mg/kg of PSL, combination therapy of steroid and mycophenolate mofetil was started. During this combination therapy, we executed pre-emptive therapy for cytomegalovirus infection twice. We should manage cancer patients with intractable irAE carefully as treatment for irAE induces a long period of severe immunosuppression.
KEYWORDS
Immune checkpoint inhibitor Immune-related adverse event (irAE) Cytomegalovirus (CMV) Pre-emptive therapy
Received 31 Jan 2020 ／ Accepted 7 Sep 2020
AJRS, 10(1): 33-36, 2021
Copyright © The Japanese Respiratory Society All Rights Reserved.